Parkinson Disease

CLINICAL NEUROLOGY
ASSIGNMENT
SUBMMITED BY:-
AMITESH NAWAL BIHARI
Physio Intern
Batch July 2021/001
Parkinson’s
Parkinson’s Disease
A progressive neurodegenerative disorder
characterized by the loss of dopaminergic
neurons in the substantia nigra of the brain.
The term Parkinsonism is used to refer to a
group of disorders that produce
abnormalities of basal ganglia function.
These are of three types:-
1. Primary Parkinsonism
2. Secondary Parkinsonism
3. Parkinsonism Plus Syndrome
Primary Parkinsonism is the most common
cause affecting approx 78% of pts.
Secondary parkinsonism results from a
number of different causes.
Parkinsonism plus syndromes refer to those
conditions with symptoms of multiple
system degeneration.
ETIOLOGY
Parkinsonian symptoms can arise from
either the neuropathological condition
PD (idiopathic PD) or other forms of
Parkinsonism .
For neuropathological PD, 90% of cases
are sporadic .
10% are of genetic origin – 6 different
gene mutations have been identified –
the Parkin genes .
Genetic forms of PD are seen more
frequently in young onset PD.
A combination of environmental factors
or toxins, genetic susceptibility, and the
aging process may account for many of
the sporadic cases .
SECONDARY PARKINSONS
Can be caused by :
1.Medications – antipsychotics & antiemetics,
lithium, reserpine, aldomet
2.Sequelae of CNS infection – Prion Diseases,
Jakob Creuzfeldt, Subacute sclerosing
panencephalitis (SSPE), HIV, post encephalitic
3.Toxin Exposure – Manganese, Rotenone,
Paraquat
4.Vascular Metabolic Disorders – Binswanger’s
Disease
5.Drug Induced – MPTP
6.Certain neurodegenerative conditions may also
exhibit Parkinsonian features, these are called
the Parkinsons Plus Syndromes – progressive
supranuclear palsy, Lewy Body Dementia
7.Trauma – Pugilistic encephalopathy
PATHOLOGY
Basal ganglia:
Group of nuclei in the brain situated at the base of the
forebrain (striatum[caudate & putamen], globus pallidus,
substantia nigra [SN], subthalamic nucleus).
Associated with voluntary motor control, procedural
learning, eye movements, cognitive and emotional
functions.
The main input structure in BG is striatum.
Input is received from all parts of cerebral cortex via
corticostriate projection & also from substancia nigra.
Output is channeled via globus pallidus & SN to thalamus
and back to cortex, completing the loop.
Direct pathway facilitates BG output to thalamus &
cortex.
Indirect pathway provides disinhibition to subthalamic
nuclei & thus suppression of some movements.
PATHOPHYSIOLOGY
Pathological hallmark of PD :
degeneration of dopaminergic
neurons in the substantia nigra
compacta, resulting in depletion of
striatal dopamine.
This neurotransmitter regulates
excitatory & inhibitory outflow from
the basal ganglia.
Loss of dopamine results in overactive
indirect pathway leading to akinesia &
rigidity.
Underactive direct pathway leads to
bradykinesia.
Some of the dopaminergic neurons
survive, and these are found to
contain Lewy Bodies.
Pathophysiology of Parkinsons
Lewy Bodies are eosinophilic
intracytoplasmic inclusions,
composed of numerous
proteins .
Protein accumulation plays a
prominent role in the
pathogenesis of both
sporadic & familial forms of
PD .
Lewy bodies may actually
be cytoprotective .
Six Cardinal Features
1. Tremor at rest
2. Rigidity
3. Bradykinesia
4. Loss of postural reflexes
5. Flexed Posture
6. Freezing (Motor Block)
Diagnostic Criteria :
Definite Parkinsons : at least two of these
features must be present, one of them being # 1
or # 2
Probable : Feature # 1 or feature # 2 is present
Possible : at least two of features # 3 – 6 must be
present
Stages of PD
(Modified Hoehn & Yahr Scale)
Stage 0 No signs of disease
Stage 1 Unilateral disease
Stage 1.5 Unilateral disease plus axial involvement
Stage 2 Bilateral disease, without impaired balance
Stage 2.5 Bilateral disease, with impaired balance
Stage 3 Mild to moderate bilateral disease, some postural
instability; physically dependent
Stage 4 Severe disability; still able to walk or stand unassisted
Stage 5 Wheelchair-bound or bedridden
Diagnostic Testing
There are no clinical tests widely available
to definitively make the diagnosis,
however, if confirmation of the clinical
diagnosis is desired, order serial 6 – fluoro
L dopa PET scans which will demonstrate a
gradual decline in uptake in the putamen &
caudate in the Parkinsons patient
Alternative Imaging Study - Serial Beta CIT
SPECT imaging revealing gradual loss of
function in the striatum
On the right, see the PET scan of a patient
who underwent implantation of fetal tissue
into the right putamen - note the recovery
of function in the right putamen and the
progressive loss of function in the left
putamen
MRI Appearance in
Parkinsons Disease
Standard MRI studies in Parkinsons
are normal.
If warranted, consider High Field
Strength 1.5 Tesla T2 weighted
Brain MRI.
Typical Appearance in Parkinsons :
wider area of lucency will be noted
in the subthalamic nucleus that is
probably indicative of increased
accumulation of iron – iron
deposition occurs when there is a
loss of connectivity to the cortex
Early Non - Specific
Generalized stiffness
Pain or Paresthesias of the limbs – in
particular, shoulder pain
Constipation
Low Uric Acid Levels
Sleeplessness
Reduction in volume of the voice
Loss of sense of smell
Seborrheic Dermatitis
These symptoms precede onset of the
motor symptoms of Parkinsons
(A Retrospective Study of Early
Symptoms of Parkinsons Disease,
Przuntek, 1992)
 Problems with fine motor skills
 Decreased sense of smell
 Loss of appetite
 Tremor occurring with anxiety
 Decreased arm swing on one side – a
principal finding in Parkinsons is
asymmetry in neurological findings
 Decreased emotional expression
 Personality changes, especially
introversion & inflexibility
Early Specific
Signs of Parkinsons
Neuropsychiatric Disorders in
Parkinsons Disease
• Depression
• Anxiety, including panic attacks
• Cognitive Dysfunction
• Dementia
• Psychosis
• Confusion or delirium
• Apathy
Treatment
No cure currently exists
Treatment does not stop the progression of the disease
Offers symptomatic relief
Can temporarily restore function
Can enhance Quality Of Life
Each individual responds to drugs differently
Medications
1. Levodopa:-
Converted to dopamine in the bone, which is responsible for transmitting signals in the brain allowing for normal
movements
Often combined with Carbidopa (Sinemet), which ↑ the amount of Levodopa that goes to the brain.
2. COMT inhibitors:-
Blocks the action of catechol-O-methyltransferase, an enzyme that breaks down dopamine.
Entacapone (Comtan) and Tolcapone (Tasmar).
3. Dopamine agonists:-
Act like dopamine within the brain
Bromocriptine (Parlodel), Pramipexole (Mirapex), Ropinirole (Requip), and Apomorphine (Apokyn).
4. Amantadine:-
Unknown mechanism; may ↑ brain’s response to dopamine or releases stored dopamine
Amantadine (Symmetrel).
5. Anticholinergics:-
Exert a relaxing effect on the body
Benztropine Mesylate (Congetin), Procyclidine (Kemadrin), Biperiden (Akineton), and Trihexyphenidyl.
6. Selegiline:-
Unknown mechanism
Appears to inhibit the breakdown of dopamine
Usually added to a patient’s therapy when effectiveness of Levodopa is ↓
Selegiline (Zalapar, Eldepyrl, Emsam)
Surgery
Deep Brain Stimulation
Brain pacemaker, sends electrical
impulses to brain to stimulate the
subthalamic nucleus.
Improves motor functions and
reduce motor complications.
Complications include: brain
hemorrhage, seizures, death.
Pallidotomy is no longer performed
in the management of Parkinsons – it
is not as effective as Deep Brain
Stimulation (DBS)
Physiotherapy Management
Aims of Physiotherapy:
1. Maintain and improve levels of function and independence, which will help to
improve a person’s quality of life
2. Use exercise and movement strategies to improve mobility
3. Correct and improve abnormal movement patterns and posture, where
possible
4. Maximise muscle strength and joint flexibility
5. Correct and improve posture and balance, and minimise risks of falls
6. Maintain a good breathing pattern and effective cough
7. Educate the person with Parkinson’s and their carer or family members
8. Enhance the effects of drug therapy
MOTOR LEARNING program
• Practice Improves learning & performance in early
stages
• Large no. of repetitions to develop procedural skills
• Avoid long & complex movement sequences
• Avoid dual tasking
• Modify environment to reduce interference of task
• Focus of Attention to the task
• Use of structured instructional sets
• Repetitive drill like practise in advanced disease
• Use of visual cues like floor markings, laser device,
visual targets.
• Rhythmic auditory stimulation like the use of
metronome beat,or a steady beat or auditory cues
• Multisensory cues ( visual + auditory).
RELAXATION EXERCISES
Gentle rocking
Slow rhythmic, rotational
movements of extremities & trunk
Rhythmic initiation technique of
PNF
Diaphragmatic breathing during
exercise
Progressive relaxation technique
Gentle yoga
Tai chi
Stress management techniques
Active and passive ROM ex. 2-3
tmes a day
Focus on strengthening weak &
elongated extensor ms, and
elongating shortened tight
flexor ms
PNF (D1/D2 patterns, contract
relax)
Stretching techniques with
mobilisation
Avoid ballistic stretches
Passive positioning ( prone
lying)
FLEXIBILITY EXERCISES
STRENGTH TRAINING
Resistive training
Isokinetic training
Functional training activities
Pool exs.
FUNCTIONAL TRAINING
• Bed mobility
• Side lying rolling
• Transition to sitting
• Pelvic tilts
• Weight shifts in sitting
• Trunk rotations in sitting
• Bilateral PNF patterns in sitting
• Transition to stand
• Weight shifts in standing
• Stepping activity
• Standing wall push ups
• Quadruped creeping
• Quadruped to kneeling to half kneeling to standing
• Use of massage, facial PNF, stretch, verbal cueing, mirror to facilitate facial movements
BALANCE TRAINING
a) Focus on center of mass (COM) and limits of
stability(LOS) control training.
b) Improve posture in sitting, standing& dynamic
movement tasks
c) practice working on expanding the limits of
stability in sitting & standing
d) Use of verbal, tactile or proprioceptive cues to
facilitate proper posture and safety awareness
e) Use of standing platform training device
f) Practice of dynamic stability tasks like wt shifts,
reaching, trunk rotation
g) Training using dynamic surface like a ball/ foam
h) Stepping/ marching in place/ heel raises/ toe
offs
i) Movement transitions
j) Altering visual inputs like eyes closed/ reduced
lighting
k) Partial wall squats
GAIT TRAINING
• Practice walk with vertical poles
• Verbal cues to ‘walk tall’
• Use of overhead harness
• Visual/ auditory cues
• Use of grids/ footprints to improve foot placement
• Marching in high stepping pattern to improve step
height
• Sidestepping/crossed step walking
• Altering the support surface
• Community walking
• Stair climbing, ramp walking
• Weight supported treadmill training
CARDIOPULMONARY TRAINING
a) Diaphragmatic breathing exs.
b) Air- shift techniques
c) Thoracic mobility exs.
d) Exs. Of neck, shoulder &Trunk ms.
e) LE/UE ergometry
f) Aerobic pool program
g) Ex frequency 3-5 days/week
Equipment
Rolling Walkers are best – canes
& standard walkers are
frequently carried by the patient.
Shower chairs
Grab Bars
Raised Toilet Seats with
armrests.
Chairs with arms to assist
patient to lower themselves to
the chair without falling.
THANK YOU
1 sur 27

Recommandé

Parkinson's Disease par
Parkinson's DiseaseParkinson's Disease
Parkinson's DiseaseDr. Syed Masood Ahmed Quadri
2.5K vues32 diapositives
Parkinson’s disease ( shobs ) par
Parkinson’s disease ( shobs )Parkinson’s disease ( shobs )
Parkinson’s disease ( shobs )Shobhit Shah
3.3K vues46 diapositives
Parkinson's disease by waheed javed par
Parkinson's disease by waheed javedParkinson's disease by waheed javed
Parkinson's disease by waheed javedWaheed javed, Student at INDUS COLLEGE OF NURSING
1.5K vues22 diapositives
Parkinson disease par
Parkinson diseaseParkinson disease
Parkinson diseaseYasser Alzainy
956 vues26 diapositives
Understanding the Brain: Final Project - Parkinson’s Disease par
Understanding the Brain: Final Project - Parkinson’s DiseaseUnderstanding the Brain: Final Project - Parkinson’s Disease
Understanding the Brain: Final Project - Parkinson’s DiseaseRachael Shaw
3.7K vues12 diapositives
Basal ganglia parkinson's disease par
Basal ganglia parkinson's diseaseBasal ganglia parkinson's disease
Basal ganglia parkinson's diseasePratap Tiwari
13.5K vues54 diapositives

Contenu connexe

Tendances

PARKINSON’S DISEASE par
PARKINSON’S DISEASEPARKINSON’S DISEASE
PARKINSON’S DISEASEDr. Kapil Dev Doddamani
15.8K vues32 diapositives
Parkinsonism & Alzheimer's disease par
Parkinsonism & Alzheimer's diseaseParkinsonism & Alzheimer's disease
Parkinsonism & Alzheimer's diseaseSurendra Chhetri
2.8K vues124 diapositives
Parkinson's diseases par
Parkinson's diseasesParkinson's diseases
Parkinson's diseasesRafiul Basher Rabby
15.3K vues37 diapositives
Parkinsonism, Parkinson’s Disease par
Parkinsonism, Parkinson’s Disease Parkinsonism, Parkinson’s Disease
Parkinsonism, Parkinson’s Disease Dr. Siddharth Dutta
569 vues42 diapositives
Atypical Parkinsonism par
Atypical ParkinsonismAtypical Parkinsonism
Atypical ParkinsonismAHMED TANJIMUL ISLAM
473 vues73 diapositives
parkinsons disease recent updates par
parkinsons disease recent updatesparkinsons disease recent updates
parkinsons disease recent updatesNeurologyKota
11.6K vues68 diapositives

Tendances(20)

parkinsons disease recent updates par NeurologyKota
parkinsons disease recent updatesparkinsons disease recent updates
parkinsons disease recent updates
NeurologyKota11.6K vues
Parkinson's Disease - Neurology par Nadia Shams
Parkinson's Disease - NeurologyParkinson's Disease - Neurology
Parkinson's Disease - Neurology
Nadia Shams2.3K vues
Progressive supranuclear palsy and multiple system atrophy par Sooraj Patil
Progressive supranuclear palsy and multiple system atrophyProgressive supranuclear palsy and multiple system atrophy
Progressive supranuclear palsy and multiple system atrophy
Sooraj Patil2.5K vues
PARKINSON'S DISEASE Presentation by Rajee par Rajee Ravindran
PARKINSON'S DISEASE  Presentation by RajeePARKINSON'S DISEASE  Presentation by Rajee
PARKINSON'S DISEASE Presentation by Rajee
Rajee Ravindran1.8K vues
Parkinson Disease par yuyuricci
Parkinson DiseaseParkinson Disease
Parkinson Disease
yuyuricci28.6K vues
Advances in Management of Parkinson's Disease par Sultana Shaikh
Advances in Management of Parkinson's DiseaseAdvances in Management of Parkinson's Disease
Advances in Management of Parkinson's Disease
Sultana Shaikh4.8K vues
Approach to dystonia by dr srimant pattnaik par srimantp
Approach to dystonia by dr srimant pattnaikApproach to dystonia by dr srimant pattnaik
Approach to dystonia by dr srimant pattnaik
srimantp282 vues
Neurosteroids and neuropeptides par Jonaid Ali
Neurosteroids and neuropeptidesNeurosteroids and neuropeptides
Neurosteroids and neuropeptides
Jonaid Ali2.6K vues

Similaire à Parkinson Disease

Parkinsons Disease par
Parkinsons DiseaseParkinsons Disease
Parkinsons Diseasetest
66.9K vues42 diapositives
Parkinsons disease V Pharm.D par
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.DDr.Sohel Memon
10.2K vues48 diapositives
Parkinson's disease par
Parkinson's diseaseParkinson's disease
Parkinson's diseaseAnindya Banerjee
109.8K vues46 diapositives
Parkinson's disease par
 Parkinson's disease Parkinson's disease
Parkinson's diseaseSunil Pahari
4.3K vues47 diapositives
Prakash park par
Prakash parkPrakash park
Prakash parkPrakash Mahala
1.7K vues35 diapositives
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera... par
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Soujanya Pharm.D
5.2K vues24 diapositives

Similaire à Parkinson Disease(20)

Parkinsons Disease par test
Parkinsons DiseaseParkinsons Disease
Parkinsons Disease
test66.9K vues
Parkinsons disease V Pharm.D par Dr.Sohel Memon
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.D
Dr.Sohel Memon10.2K vues
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera... par Soujanya Pharm.D
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Soujanya Pharm.D5.2K vues
non motor manifestation of parkinson disease par Osama Ragab
non motor manifestation of parkinson diseasenon motor manifestation of parkinson disease
non motor manifestation of parkinson disease
Osama Ragab3K vues
Cns Parkinson Davidson 07. par Shaikhani.
Cns Parkinson Davidson 07.Cns Parkinson Davidson 07.
Cns Parkinson Davidson 07.
Shaikhani.3.5K vues
Parkinson's Disease & Physiotherapy Management par Anumeha Sharma
Parkinson's Disease & Physiotherapy Management Parkinson's Disease & Physiotherapy Management
Parkinson's Disease & Physiotherapy Management
Anumeha Sharma 6.6K vues
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT par Srinitha Busam
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
Srinitha Busam1.5K vues
Parkinsonism.ppt par Shama
Parkinsonism.pptParkinsonism.ppt
Parkinsonism.ppt
Shama7.3K vues

Dernier

Small Intestine.pptx par
Small Intestine.pptxSmall Intestine.pptx
Small Intestine.pptxMathew Joseph
237 vues50 diapositives
Buccoadhesive drug delivery System.pptx par
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptxABG
162 vues43 diapositives
Biomedicine & Pharmacotherapy par
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & PharmacotherapyTrustlife
207 vues12 diapositives
Thrives Priority Areas: Behavioral Health par
Thrives Priority Areas: Behavioral HealthThrives Priority Areas: Behavioral Health
Thrives Priority Areas: Behavioral HealthCity of Chesapeake
82 vues22 diapositives
Calcutta Clinical Course - Allen College of Homoeopathy par
Calcutta Clinical Course - Allen College of HomoeopathyCalcutta Clinical Course - Allen College of Homoeopathy
Calcutta Clinical Course - Allen College of HomoeopathyAllen College
86 vues32 diapositives
Nidanarthakara Roga.pptx par
Nidanarthakara Roga.pptxNidanarthakara Roga.pptx
Nidanarthakara Roga.pptxAkshay Shetty
63 vues23 diapositives

Dernier(20)

Buccoadhesive drug delivery System.pptx par ABG
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptx
ABG162 vues
Biomedicine & Pharmacotherapy par Trustlife
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy
Trustlife207 vues
Calcutta Clinical Course - Allen College of Homoeopathy par Allen College
Calcutta Clinical Course - Allen College of HomoeopathyCalcutta Clinical Course - Allen College of Homoeopathy
Calcutta Clinical Course - Allen College of Homoeopathy
Allen College86 vues
Extraordinary Far Infrared Technology - Raising Frequencies with far infrared... par corey268189
Extraordinary Far Infrared Technology - Raising Frequencies with far infrared...Extraordinary Far Infrared Technology - Raising Frequencies with far infrared...
Extraordinary Far Infrared Technology - Raising Frequencies with far infrared...
corey26818947 vues
eTEP -RS Dr.TVR.pptx par Varunraju9
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptx
Varunraju9145 vues
Complications & Solutions in Laparoscopic Hernia Surgery.pptx par Varunraju9
Complications & Solutions in Laparoscopic Hernia Surgery.pptxComplications & Solutions in Laparoscopic Hernia Surgery.pptx
Complications & Solutions in Laparoscopic Hernia Surgery.pptx
Varunraju9134 vues
Pulmonary Embolism for Nurses.pptx par Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain35 vues
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx par ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG117 vues
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx par ABG
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptxICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx
ABG64 vues

Parkinson Disease

  • 1. CLINICAL NEUROLOGY ASSIGNMENT SUBMMITED BY:- AMITESH NAWAL BIHARI Physio Intern Batch July 2021/001
  • 3. Parkinson’s Disease A progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra of the brain. The term Parkinsonism is used to refer to a group of disorders that produce abnormalities of basal ganglia function. These are of three types:- 1. Primary Parkinsonism 2. Secondary Parkinsonism 3. Parkinsonism Plus Syndrome Primary Parkinsonism is the most common cause affecting approx 78% of pts. Secondary parkinsonism results from a number of different causes. Parkinsonism plus syndromes refer to those conditions with symptoms of multiple system degeneration.
  • 4. ETIOLOGY Parkinsonian symptoms can arise from either the neuropathological condition PD (idiopathic PD) or other forms of Parkinsonism . For neuropathological PD, 90% of cases are sporadic . 10% are of genetic origin – 6 different gene mutations have been identified – the Parkin genes . Genetic forms of PD are seen more frequently in young onset PD. A combination of environmental factors or toxins, genetic susceptibility, and the aging process may account for many of the sporadic cases .
  • 5. SECONDARY PARKINSONS Can be caused by : 1.Medications – antipsychotics & antiemetics, lithium, reserpine, aldomet 2.Sequelae of CNS infection – Prion Diseases, Jakob Creuzfeldt, Subacute sclerosing panencephalitis (SSPE), HIV, post encephalitic 3.Toxin Exposure – Manganese, Rotenone, Paraquat 4.Vascular Metabolic Disorders – Binswanger’s Disease 5.Drug Induced – MPTP 6.Certain neurodegenerative conditions may also exhibit Parkinsonian features, these are called the Parkinsons Plus Syndromes – progressive supranuclear palsy, Lewy Body Dementia 7.Trauma – Pugilistic encephalopathy
  • 6. PATHOLOGY Basal ganglia: Group of nuclei in the brain situated at the base of the forebrain (striatum[caudate & putamen], globus pallidus, substantia nigra [SN], subthalamic nucleus). Associated with voluntary motor control, procedural learning, eye movements, cognitive and emotional functions. The main input structure in BG is striatum. Input is received from all parts of cerebral cortex via corticostriate projection & also from substancia nigra. Output is channeled via globus pallidus & SN to thalamus and back to cortex, completing the loop. Direct pathway facilitates BG output to thalamus & cortex. Indirect pathway provides disinhibition to subthalamic nuclei & thus suppression of some movements.
  • 7. PATHOPHYSIOLOGY Pathological hallmark of PD : degeneration of dopaminergic neurons in the substantia nigra compacta, resulting in depletion of striatal dopamine. This neurotransmitter regulates excitatory & inhibitory outflow from the basal ganglia. Loss of dopamine results in overactive indirect pathway leading to akinesia & rigidity. Underactive direct pathway leads to bradykinesia. Some of the dopaminergic neurons survive, and these are found to contain Lewy Bodies.
  • 8. Pathophysiology of Parkinsons Lewy Bodies are eosinophilic intracytoplasmic inclusions, composed of numerous proteins . Protein accumulation plays a prominent role in the pathogenesis of both sporadic & familial forms of PD . Lewy bodies may actually be cytoprotective .
  • 9. Six Cardinal Features 1. Tremor at rest 2. Rigidity 3. Bradykinesia 4. Loss of postural reflexes 5. Flexed Posture 6. Freezing (Motor Block) Diagnostic Criteria : Definite Parkinsons : at least two of these features must be present, one of them being # 1 or # 2 Probable : Feature # 1 or feature # 2 is present Possible : at least two of features # 3 – 6 must be present
  • 10. Stages of PD (Modified Hoehn & Yahr Scale) Stage 0 No signs of disease Stage 1 Unilateral disease Stage 1.5 Unilateral disease plus axial involvement Stage 2 Bilateral disease, without impaired balance Stage 2.5 Bilateral disease, with impaired balance Stage 3 Mild to moderate bilateral disease, some postural instability; physically dependent Stage 4 Severe disability; still able to walk or stand unassisted Stage 5 Wheelchair-bound or bedridden
  • 11. Diagnostic Testing There are no clinical tests widely available to definitively make the diagnosis, however, if confirmation of the clinical diagnosis is desired, order serial 6 – fluoro L dopa PET scans which will demonstrate a gradual decline in uptake in the putamen & caudate in the Parkinsons patient Alternative Imaging Study - Serial Beta CIT SPECT imaging revealing gradual loss of function in the striatum On the right, see the PET scan of a patient who underwent implantation of fetal tissue into the right putamen - note the recovery of function in the right putamen and the progressive loss of function in the left putamen
  • 12. MRI Appearance in Parkinsons Disease Standard MRI studies in Parkinsons are normal. If warranted, consider High Field Strength 1.5 Tesla T2 weighted Brain MRI. Typical Appearance in Parkinsons : wider area of lucency will be noted in the subthalamic nucleus that is probably indicative of increased accumulation of iron – iron deposition occurs when there is a loss of connectivity to the cortex
  • 13. Early Non - Specific Generalized stiffness Pain or Paresthesias of the limbs – in particular, shoulder pain Constipation Low Uric Acid Levels Sleeplessness Reduction in volume of the voice Loss of sense of smell Seborrheic Dermatitis These symptoms precede onset of the motor symptoms of Parkinsons (A Retrospective Study of Early Symptoms of Parkinsons Disease, Przuntek, 1992)  Problems with fine motor skills  Decreased sense of smell  Loss of appetite  Tremor occurring with anxiety  Decreased arm swing on one side – a principal finding in Parkinsons is asymmetry in neurological findings  Decreased emotional expression  Personality changes, especially introversion & inflexibility Early Specific Signs of Parkinsons
  • 14. Neuropsychiatric Disorders in Parkinsons Disease • Depression • Anxiety, including panic attacks • Cognitive Dysfunction • Dementia • Psychosis • Confusion or delirium • Apathy
  • 15. Treatment No cure currently exists Treatment does not stop the progression of the disease Offers symptomatic relief Can temporarily restore function Can enhance Quality Of Life Each individual responds to drugs differently
  • 16. Medications 1. Levodopa:- Converted to dopamine in the bone, which is responsible for transmitting signals in the brain allowing for normal movements Often combined with Carbidopa (Sinemet), which ↑ the amount of Levodopa that goes to the brain. 2. COMT inhibitors:- Blocks the action of catechol-O-methyltransferase, an enzyme that breaks down dopamine. Entacapone (Comtan) and Tolcapone (Tasmar). 3. Dopamine agonists:- Act like dopamine within the brain Bromocriptine (Parlodel), Pramipexole (Mirapex), Ropinirole (Requip), and Apomorphine (Apokyn). 4. Amantadine:- Unknown mechanism; may ↑ brain’s response to dopamine or releases stored dopamine Amantadine (Symmetrel). 5. Anticholinergics:- Exert a relaxing effect on the body Benztropine Mesylate (Congetin), Procyclidine (Kemadrin), Biperiden (Akineton), and Trihexyphenidyl. 6. Selegiline:- Unknown mechanism Appears to inhibit the breakdown of dopamine Usually added to a patient’s therapy when effectiveness of Levodopa is ↓ Selegiline (Zalapar, Eldepyrl, Emsam)
  • 17. Surgery Deep Brain Stimulation Brain pacemaker, sends electrical impulses to brain to stimulate the subthalamic nucleus. Improves motor functions and reduce motor complications. Complications include: brain hemorrhage, seizures, death. Pallidotomy is no longer performed in the management of Parkinsons – it is not as effective as Deep Brain Stimulation (DBS)
  • 18. Physiotherapy Management Aims of Physiotherapy: 1. Maintain and improve levels of function and independence, which will help to improve a person’s quality of life 2. Use exercise and movement strategies to improve mobility 3. Correct and improve abnormal movement patterns and posture, where possible 4. Maximise muscle strength and joint flexibility 5. Correct and improve posture and balance, and minimise risks of falls 6. Maintain a good breathing pattern and effective cough 7. Educate the person with Parkinson’s and their carer or family members 8. Enhance the effects of drug therapy
  • 19. MOTOR LEARNING program • Practice Improves learning & performance in early stages • Large no. of repetitions to develop procedural skills • Avoid long & complex movement sequences • Avoid dual tasking • Modify environment to reduce interference of task • Focus of Attention to the task • Use of structured instructional sets • Repetitive drill like practise in advanced disease • Use of visual cues like floor markings, laser device, visual targets. • Rhythmic auditory stimulation like the use of metronome beat,or a steady beat or auditory cues • Multisensory cues ( visual + auditory).
  • 20. RELAXATION EXERCISES Gentle rocking Slow rhythmic, rotational movements of extremities & trunk Rhythmic initiation technique of PNF Diaphragmatic breathing during exercise Progressive relaxation technique Gentle yoga Tai chi Stress management techniques Active and passive ROM ex. 2-3 tmes a day Focus on strengthening weak & elongated extensor ms, and elongating shortened tight flexor ms PNF (D1/D2 patterns, contract relax) Stretching techniques with mobilisation Avoid ballistic stretches Passive positioning ( prone lying) FLEXIBILITY EXERCISES
  • 21. STRENGTH TRAINING Resistive training Isokinetic training Functional training activities Pool exs.
  • 22. FUNCTIONAL TRAINING • Bed mobility • Side lying rolling • Transition to sitting • Pelvic tilts • Weight shifts in sitting • Trunk rotations in sitting • Bilateral PNF patterns in sitting • Transition to stand • Weight shifts in standing • Stepping activity • Standing wall push ups • Quadruped creeping • Quadruped to kneeling to half kneeling to standing • Use of massage, facial PNF, stretch, verbal cueing, mirror to facilitate facial movements
  • 23. BALANCE TRAINING a) Focus on center of mass (COM) and limits of stability(LOS) control training. b) Improve posture in sitting, standing& dynamic movement tasks c) practice working on expanding the limits of stability in sitting & standing d) Use of verbal, tactile or proprioceptive cues to facilitate proper posture and safety awareness e) Use of standing platform training device f) Practice of dynamic stability tasks like wt shifts, reaching, trunk rotation g) Training using dynamic surface like a ball/ foam h) Stepping/ marching in place/ heel raises/ toe offs i) Movement transitions j) Altering visual inputs like eyes closed/ reduced lighting k) Partial wall squats
  • 24. GAIT TRAINING • Practice walk with vertical poles • Verbal cues to ‘walk tall’ • Use of overhead harness • Visual/ auditory cues • Use of grids/ footprints to improve foot placement • Marching in high stepping pattern to improve step height • Sidestepping/crossed step walking • Altering the support surface • Community walking • Stair climbing, ramp walking • Weight supported treadmill training
  • 25. CARDIOPULMONARY TRAINING a) Diaphragmatic breathing exs. b) Air- shift techniques c) Thoracic mobility exs. d) Exs. Of neck, shoulder &Trunk ms. e) LE/UE ergometry f) Aerobic pool program g) Ex frequency 3-5 days/week
  • 26. Equipment Rolling Walkers are best – canes & standard walkers are frequently carried by the patient. Shower chairs Grab Bars Raised Toilet Seats with armrests. Chairs with arms to assist patient to lower themselves to the chair without falling.